Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk remains a sell due to increased competition ... which were labeled as close to patent expiration in the 2023 20-F filing. These two drugs contributed to Novo's sales, but as can ...

Novo Nordisk and Ascendis Pharma have agreed to ... As per the deal signed yesterday (4 November), the two Danish companies will jointly develop therapeutics for metabolic and cardiovascular ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations.

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range. The maker ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity ... has been on the shortage list for over two years, with different doses being listed in shortage at various times.

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

The company is due to release data before the end of this year from a late-stage trial of CagriSema, a two-drug combination ... coverage of Danish drugmaker Novo Nordisk and its race to increase ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...